Our previous blog posts, Artificial Intelligence as the Inventor of Life Sciences Patents? and Update on Artificial Intelligence: Court Rules that AI Cannot Qualify As “Inventor,” discuss recent inventorship issues surrounding AI and its implications for life sciences innovations. Continuing our series, we now look at the appeal recently filed by Stephen Thaler (“Thaler”) in his quest to obtain a patent for an invention created by AI in the absence of a traditional human inventor. 

As we previously reported, on September 3, 2021, the U.S. District Court for the Eastern District of Virginia ruled that an AI machine cannot qualify as an “inventor” under the Patent Act, in a case that Thaler filed seeking, among other things, an order compelling the USPTO to reinstate his patent applications. Those patent applications name an AI system called “Device for Autonomous Bootstrapping of Unified Sentience” aka “DABUS,” as the sole inventor. Thaler, who developed DABUS, remains the owner of any patent rights stemming from these applications. The first application is directed to a design of a container based on fractal geometry. The second application is directed to a device and method for producing light that flickers rhythmically in a specific pattern mimicking human neural activity.  According to Thaler, he could not list himself as the inventor, as he did not contribute to the conception of the inventions; instead DABUS performed what is traditionally considered the mental part of the inventive act.

On appeal, Thaler argues for an expansive reading of the Patent Act’s inventorship requirement on both technical and policy grounds. He asserts that the plain language of the Patent Act permits patents to non-human inventors because terms like “individual,” “person,” and pronouns referring to such entities are broad terms not limited to natural persons, and in their plain meaning can include AI. Thaler further argues that the USPTO is being inconsistent with its interpretation of the language of the Patent Act in limiting these terms to mean natural persons when it comes to AI inventorship.  For instance, 35 U.S.C. § 271(a) uses the term “whoever” to refer to infringing entities and the USPTO in the past has interpreted “whoever” to mean either a natural person or not a natural person.  Thaler also points to the Patent Act’s use of the term “person,” and not “natural person,” as evidencing a deliberate choice to not exclude a broader category of inventors.

Existing case law that precludes corporations and state sovereigns from qualifying as inventors are inapposite according to Thaler because when a corporation files for a patent application, there will always be at least one natural person who qualifies as an inventor and can be named as such on the patent application. The same is not true for AI. Cases contrasting corporations with “natural persons” do not address the question posed by an AI-generated invention and should not be read more broadly than the scope of the questions presented in those cases.  As Thaler states in his appeal brief “[n]o case states a general principle that language like ‘individual’ or “person,” and subject pronouns must mean a human being, because similarly anthropomorphized language can refer to entities that are not natural persons, and such language has been interpreted to include other entities.”

According to Thaler, another reason the plain language of the Patent Act permits patents to non-human inventors is that there is no “conception” requirement prohibiting patents on AI-generated inventions. Conception has been defined as the formation in the mind of the inventor of a definite and permanent idea of the complete and operative invention. Because both of the patent applications-in-suit meet the enablement and written description requirements, they by necessity contain a definite and permanent idea of a complete and operative invention. That is, according to Thaler, the filing of each patent application itself serves as conception and constructive reduction to practice of the subject matter described in the application. Further, Thaler argues that, historically, conception was only relevant to establishing priority of inventorship (e.g., in an interference proceeding or antedating a prior art reference) and thus ownership of a patent application, but not as a basis for denying patent protection.

Finally, Thaler proposes that granting patents to AI-generated inventions is consistent with congressional intent in that granting patents to AI-generated inventions encourages inventions, their public disclosure, and their commercialization. According to Thaler “[i]t would run contrary to the purpose of the patent system to only allow an AI’s owner to own AI output as a trade secret but not to encourage the information’s disclosure in return for patent protection.” Thaler argues that interpreting the Patent Act’s language to advance its purpose is particularly appropriate where, as here, there is no evidence that Congress anticipated and legislated for AI-generated inventions. Thaler further supports this point by noting that as technology has advanced, patent law has historically evolved to accommodate and further encourage such advances. On the other hand, excluding an entire cutting-edge class of inventions from patentability would undermine the patent system and ultimately frustrate innovation. In Thaler’s words: “While other countries are promoting the progress of science, the USPTO is belatedly adopting luddism.”

We will continue to monitor this appeal as it has important implications for life sciences companies employing AI technologies.

Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Xin Hu Rasmussen

Xin Hu Rasmussen, Ph.D. is an associate in the Patent Law and Intellectual Property Groups. Her primary focus is assisting patent prosecution in the fields of electrical engineering and computer science.

Xin has drafted and prosecuted patent applications in a broad range of…

Xin Hu Rasmussen, Ph.D. is an associate in the Patent Law and Intellectual Property Groups. Her primary focus is assisting patent prosecution in the fields of electrical engineering and computer science.

Xin has drafted and prosecuted patent applications in a broad range of fields, including semiconductor processing, software, circuit designs, MEMS technology, medical devices and surgical instruments. She also has analyzed patent issues in the context of due diligence regarding patentability, validity, infringement and freedom to operate.

While pursuing her Ph.D. at the Massachusetts Institute of Technology under the supervision of Jacob White and Luca Daniels, Xin wrote a thesis on numerical simulations of the electromagnetic behavior of semiconductors over different types of substrate and in response to different operating frequencies.

Photo of Baldassare Vinti Baldassare Vinti

Baldassare (“Baldo”) Vinti co-heads Proskauer’s Intellectual Property Litigation Group.

Baldo’s practice focuses on litigating patent, false advertising, trade secret, life sciences, trademark and contractual matters in federal and state courts and before the International Trade Commission. He is a seasoned trial attorney responsible…

Baldassare (“Baldo”) Vinti co-heads Proskauer’s Intellectual Property Litigation Group.

Baldo’s practice focuses on litigating patent, false advertising, trade secret, life sciences, trademark and contractual matters in federal and state courts and before the International Trade Commission. He is a seasoned trial attorney responsible for all aspects of litigation, including Markman hearings, appeals before the Federal Circuit, case preparation and strategy, depositions, motion practice, and settlement negotiations. He has represented clients in high-stakes matters involving a broad range of technologies, including medical devices, diagnostics, immunoassays, prosthetics, pharmaceuticals, dental implants, electronic medical records systems, encryption technology, wound dressings, digital video compression, electronic book delivery and security systems, mobile media technologies, navigation and location-based services, bandwidth management, bar code scanning, lasers , and other technologies. Baldo has represented numerous major corporations, including Arkema S.A., British Telecommunications PLC, Church & Dwight Co., Inc., Henry Schein, Inc., Maidenform Brands Inc., Mitsubishi Electric Corp., Ossur North America Inc., Panasonic Corp., Sony Corp., Welch Foods, Inc., and Zenith Electronics LLC.

In addition, Baldo regularly handles transactional work, including intellectual property due diligence, licensing, intellectual property structural transactions, patentability studies, infringement/non-infringement opinions, and client counseling in intellectual property matters.

Baldo is an author and frequent commentator on patent issues pertaining to medical devices and a host of other intellectual property topics, and has been quoted in the National Law Journal, Bloomberg BNA, Law360, Westlaw Journal and Inside Counsel magazine. He is also a regular contributor of articles published in Medical Product Outsourcing magazine that deal with the medical device industry.

Baldo served as a judicial intern for Hon. John E. Sprizzo of the United States District Court for the Southern District of New York and for Hon. Charles A. LaTorella of the New York Supreme Court.